Loading
Lipid Metabolism and Disorders / Nutrition, Genetics, and Disease · Review
Nutrients · July 20, 2026
Raises a question worth testing. It does not answer one.
This narrative review identifies six common genetic loci (APOA1, APOE, LIPC, LPL, ANGPTL3, FADS1/2) with reported genotype-by-diet interactions in lipid metabolism and cardiovascular risk, but explicitly frames all locus-specific dietary recommendations as hypothesis-generating. The authors acknowledge that analytical validity, clinical validity, clinical utility, and evidence-supported management have not yet been fully demonstrated for these 'candidate-actionable' loci.
Narrative review. Literature on common SNPs in six candidate loci associated with CVD risk and lipid metabolism.
Six loci (APOA1, APOE, LIPC, LPL, ANGPTL3, FADS1/2) show genotype-by-diet interactions in observational and small interventional studies Two illustrative epistatic axes are discussed: APOE ε4 × FADS major T-allele and ANGPTL3 × LPL Locus-specific dietary considerations are framed as hypothesis-generating pending validation in adequately powered, genotype-stratified prospective trials
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and patients should recognize that while common SNPs in these six loci are increasingly accessible through genetic testing platforms and show associations with CVD risk and diet-genotype interactions, they should not yet be used for individual clinical management decisions. Further prospective, adequately powered trials stratified by genotype are needed before clinical utility can be established.
This is a narrative review that synthesizes observational and small interventional studies to frame six genetic loci as hypothesis-generating for diet-genotype interactions, explicitly acknowledging that the full chain of clinical validity and utility has not been demonstrated.
As stated by the source record.
Clinicians and patients should recognize that while common SNPs in these six loci are increasingly accessible through genetic testing platforms and show associations with CVD risk and diet-genotype interactions, they should not yet be used for individual clinical management decisions. Further prospective, adequately powered trials stratified by genotype are needed before clinical utility can be established.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Genomic testing for rare, highly penetrant cardiovascular pathogenic mutations is well established, but its scarcity limits broader clinical utility. As cardiogenomics matures, common single nucleotide polymorphisms (SNPs) associated with cardiovascular disease (CVD) risk are increasingly accessible to clinicians and patients through both clinician-ordered and direct-to-consumer (DTC) platforms. This narrative review synthesizes evidence for six common loci-APOA1, APOE, LIPC, LPL, ANGPTL3, and FADS1/2, here termed "candidate-actionable" in the limited sense that genotype-by-diet associations have been described, but the full chain of analytical validity, clinical validity, clinical utility, and evidence-supported management has not been demonstrated-that modulate lipid metabolism and CVD risk and that show genotype-by-diet interactions in observational and small interventional studies. We frame these loci as complementary to validated polygenic risk scores (PRSs), discuss two illustrative epistatic axes (APOE ε4 × FADS major T-allele; ANGPTL3 × LPL), summarize emerging epigenetic modulators of the same loci, and propose an integrated framework combining PRS, locus-level SNPs, and epigenetic state. All locus-specific dietary considerations are explicitly framed as hypothesis-generating pending validation in adequately powered, genotype-stratified prospective trials. A comparison of consumer and clinical testing platforms-updated to reflect recent ownership and regulatory changes-is provided.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.